As we know, Axiron is marketed by Eli Lilly. One would have thought if you are going to outsource your sales and marketing, you would enter into an agreement with that organization which motivates them to sell more. Unfortunately in our case, we have an agreement which penalises Lilly if they sell much more Axiron, as they they have to cut Acrux a fat cheque (bonus payment). Why would Lilly expend resources on selling more?
- Forums
- ASX - By Stock
- ACR
- Next quarterly due soon
ACR
acrux limited
Add to My Watchlist
0.00%
!
1.9¢

Next quarterly due soon, page-3
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.747M |
Open | High | Low | Value | Volume |
1.9¢ | 1.9¢ | 1.9¢ | $5.562K | 292.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 381825 | 1.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.0¢ | 60000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 331825 | 0.019 |
3 | 381800 | 0.018 |
1 | 175000 | 0.017 |
1 | 66732 | 0.015 |
1 | 70000 | 0.014 |
Price($) | Vol. | No. |
---|---|---|
0.020 | 60000 | 2 |
0.021 | 177000 | 1 |
0.022 | 18000 | 1 |
0.023 | 73278 | 3 |
0.024 | 254102 | 7 |
Last trade - 15.04pm 20/06/2025 (20 minute delay) ? |
Featured News
ACR (ASX) Chart |